CN106999548A - 半乳糖凝集素免疫疗法 - Google Patents

半乳糖凝集素免疫疗法 Download PDF

Info

Publication number
CN106999548A
CN106999548A CN201580048553.7A CN201580048553A CN106999548A CN 106999548 A CN106999548 A CN 106999548A CN 201580048553 A CN201580048553 A CN 201580048553A CN 106999548 A CN106999548 A CN 106999548A
Authority
CN
China
Prior art keywords
galectin
mammal
cells
mice
immunity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580048553.7A
Other languages
English (en)
Chinese (zh)
Inventor
M·威克斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
QIMR Berghofer Medical Research Institute
Original Assignee
Queensland Institute of Medical Research QIMR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014902709A external-priority patent/AU2014902709A0/en
Application filed by Queensland Institute of Medical Research QIMR filed Critical Queensland Institute of Medical Research QIMR
Publication of CN106999548A publication Critical patent/CN106999548A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1732—Lectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4724—Lectins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
CN201580048553.7A 2014-07-14 2015-07-14 半乳糖凝集素免疫疗法 Pending CN106999548A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2014902709A AU2014902709A0 (en) 2014-07-14 Galectin immunotherapy
AU2014902709 2014-07-14
AU2014904466A AU2014904466A0 (en) 2014-11-06 Galectin immunotherapy
AU2014904466 2014-11-06
PCT/AU2015/050393 WO2016008005A1 (en) 2014-07-14 2015-07-14 Galectin immunotherapy

Publications (1)

Publication Number Publication Date
CN106999548A true CN106999548A (zh) 2017-08-01

Family

ID=55077738

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580048553.7A Pending CN106999548A (zh) 2014-07-14 2015-07-14 半乳糖凝集素免疫疗法

Country Status (10)

Country Link
US (2) US20170152317A1 (cg-RX-API-DMAC7.html)
EP (1) EP3169349A4 (cg-RX-API-DMAC7.html)
JP (2) JP2017521445A (cg-RX-API-DMAC7.html)
KR (1) KR20170040796A (cg-RX-API-DMAC7.html)
CN (1) CN106999548A (cg-RX-API-DMAC7.html)
AU (1) AU2015291783B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017000667A2 (cg-RX-API-DMAC7.html)
CA (1) CA2954678A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201700281SA (cg-RX-API-DMAC7.html)
WO (1) WO2016008005A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180044422A1 (en) * 2016-07-29 2018-02-15 New York University Treating solid tumor by targeting dectin-1 signaling
CN118085109A (zh) * 2016-08-11 2024-05-28 昆士兰医学研究所理事会 免疫调节化合物
WO2018027281A1 (en) * 2016-08-11 2018-02-15 The Council Of The Queensland Institute Of Medical Research Immune status biomarkers and uses therefor
WO2019084553A1 (en) 2017-10-27 2019-05-02 New York University ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF
KR20220030934A (ko) * 2019-05-31 2022-03-11 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 항-gal9 면역-억제 결합 분자
SG11202113222PA (en) * 2019-05-31 2021-12-30 Council Queensland Inst Medical Res Activating anti-gal9 binding molecules
WO2021022256A1 (en) * 2019-08-01 2021-02-04 New York University Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1744910A (zh) * 2003-01-24 2006-03-08 株式会社嘉尔药物 含有半乳凝素9的医药
CN1795206A (zh) * 2003-04-28 2006-06-28 株式会社嘉尔药物 半乳糖凝集素-9诱导因子
CN101070540A (zh) * 2000-04-28 2007-11-14 约翰霍普金斯大学 新的树突状细胞共刺激分子
WO2012177788A1 (en) * 2011-06-20 2012-12-27 La Jolla Institute For Allergy And Immunology Modulators of 4-1bb and immune responses
CN103314102A (zh) * 2010-12-09 2013-09-18 株式会社嘉尔药物 分泌半乳糖凝集素9的细胞、其制造方法及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030219B2 (en) * 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
WO2002000692A2 (en) * 2000-06-28 2002-01-03 Genetics Institute, Llc. Pd-l2 molecules: pd-1 ligands and uses therefor
JP2003189874A (ja) * 2001-12-28 2003-07-08 Galpharma Co Ltd ガレクチン−9活性制御剤
EP2889309B1 (en) * 2006-03-03 2017-12-27 Ono Pharmaceutical Co., Ltd. Multimer of extracellular domain of pd-1 or pd-l1
JP2011514895A (ja) * 2008-02-29 2011-05-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 精製免疫グロブリン融合タンパク質およびその精製方法
WO2010098788A2 (en) * 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
WO2010084999A1 (en) * 2009-01-26 2010-07-29 Protegene, Inc. Immunosuppressive agents and prophylactic and therapeutic agents for autoimmune diseases
EP2504028A4 (en) * 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101070540A (zh) * 2000-04-28 2007-11-14 约翰霍普金斯大学 新的树突状细胞共刺激分子
CN1744910A (zh) * 2003-01-24 2006-03-08 株式会社嘉尔药物 含有半乳凝素9的医药
CN1795206A (zh) * 2003-04-28 2006-06-28 株式会社嘉尔药物 半乳糖凝集素-9诱导因子
CN103314102A (zh) * 2010-12-09 2013-09-18 株式会社嘉尔药物 分泌半乳糖凝集素9的细胞、其制造方法及其用途
WO2012177788A1 (en) * 2011-06-20 2012-12-27 La Jolla Institute For Allergy And Immunology Modulators of 4-1bb and immune responses

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
IP LEWKOWICH ET AL.: "PD-L2 modulates asthma severity by directly decreasing dendritic cell IL-12 production", 《ARTICLES》 *
KEIKO NAGAHARA ET AL.: "Galectin-9 Increases Tim-3 Dendritic Cells and CD8+ T Cells and Enhances Antitumor Immunity via alectin-9-Tim-3 nteractions", 《THE JOURNAL OF IMMUNOLOGY》 *
MACHIKO SHIMMURA-TOMITA ET AL.: "Galectin-9-Mediated Protection from Allo-Specific T Cells as a Mechanism of Immune Privilege of Corneal Allografts", 《PLOS ONE》 *
XINGLUO LIU ET AL.: "B7DC/PDL2 Promotes Tumor Immunity by a PD-1-independent Mechanism", 《JOURNAL OF EXPERIMENTAL MEDICINE》 *

Also Published As

Publication number Publication date
JP2017521445A (ja) 2017-08-03
AU2015291783B2 (en) 2018-07-26
EP3169349A4 (en) 2018-02-14
US20190127474A1 (en) 2019-05-02
AU2015291783A1 (en) 2017-03-02
EP3169349A1 (en) 2017-05-24
SG11201700281SA (en) 2017-02-27
CA2954678A1 (en) 2016-01-21
KR20170040796A (ko) 2017-04-13
JP2021105055A (ja) 2021-07-26
BR112017000667A2 (en) 2018-01-09
WO2016008005A1 (en) 2016-01-21
US20170152317A1 (en) 2017-06-01

Similar Documents

Publication Publication Date Title
US20190127474A1 (en) Galectin immunotherapy
Boyle et al. Influence of cellular location of expressed antigen on the efficacy of DNA vaccination: cytotoxic T lymphocyte and antibody responses are suboptimal when antigen is cytoplasmic after intramuscular DNA immunization.
JP2021176880A (ja) Il−15ベース分子及びその使用方法
RU2766693C2 (ru) Комбинация, включающая иммуностимулирующие олигонуклеотиды
Casares et al. Immune evasion by malaria parasites: a challenge for vaccine development
JP2015516376A (ja) T細胞エピトープを含む、b細胞受容体複合体結合タンパク質
US20240390487A1 (en) Tlr agonists for reducing activation-induced pd-1 expression on t cells and methods of use
JP2022553192A (ja) 癌ワクチン
Stanisic et al. Examining cellular immune responses to inform development of a blood-stage malaria vaccine
Schussek et al. Immunization with apical membrane antigen 1 confers sterile infection-blocking immunity against Plasmodium sporozoite challenge in a rodent model
Bergmann-Leitner et al. C3d binding to the circumsporozoite protein carboxy-terminus deviates immunity against malaria
Lepenies et al. CTLA-4 blockade differentially influences the outcome of non-lethal and lethal Plasmodium yoelii infections
Singh et al. Centrin-Deleted Leishmania donovani Parasites Help CD4+ T Cells to Acquire Th1 Phenotype and Multi-Functionality Through Downregulation of CD200–CD200R Immune Inhibitory Axis
Wang et al. DC targeting DNA vaccines induce protective and therapeutic antitumor immunity in mice
WO2017136686A1 (en) Cross-regulation of type i interferon signaling pathways
US8206725B2 (en) Immunogenic agent and pharmaceutical composition for use against homologous and heterologous pathogens including plasmodium SPP
JP2023527067A (ja) 免疫調節複合体および治療のためのその使用
EP2537932B1 (en) Compositions for and methods of identifying antigens
US8846050B2 (en) N-domain of carcinoembryonic antigen and compositions, methods and uses thereof
Wykes et al. Adaptive immunity to Plasmodium blood stages
Barclay et al. Mixed allele malaria vaccines: host protection and within-host selection
Gbedande et al. Boosting Live Malaria Vaccine with Cytomegalovirus Vector Can Prolong Immunity through Innate and Adaptive Mechanisms
Gbedande et al. Heightened innate immune state induced by viral vector leads to enhanced response to challenge and prolongs malaria vaccine protection
Poston T-cell Dependent and independent mechanisms of chlamydial eradication and control
Adaszek et al. Quantitative changes in selected lymphocyte subpopulations after administration of a soluble parasitic antigen of Babesia canis to dogs

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170801

WD01 Invention patent application deemed withdrawn after publication